Published: 2016-12-27

Mixed germ cell tumour complicated by pulmonary thromboembolism: a case report

Hema Priya Kukreja, Prathap Talwar, Ambarish Bhandiwad


Malignant ovarian germ cell tumours (MOGCTs) are a heterogeneous group of tumours that have several histological different types derived from primordial germ cells of the embryonic gonad. They account for less than 5% of all ovarian malignancies, and are seen in the second and third decade of life. The majority of germ cell tumours are diagnosed in the early stages. Histology, FIGO stage and residual tumour after surgery are the most important prognostic factors. Recent multimodality therapy with staging laparotomy and conservative surgery, followed by platinum based chemotherapy, is associated with survival rates of 60 - 80%, even in patients with advanced disease. Mixed germ cell tumours are extremely rare and the prognosis depends on the size of each component of the tumour. The exact incidence of thrombo embolic events in patients with malignancy is difficult to determine. However ovarian malignancy is strongly associated with venous thrombo embolism. We report a case of a fourteen year old girl with a mixed GCT, with elements of yolk sac tumour and embryonal carcinoma, who succumbed to pulmonary thromboembolism.


MOGCT, Pulmonary thromboembolism

Full Text:



Weinberg LE, Lurain JR, Sing DK, Schink JC. Survival and reproductive outcomes in women treated for malignant ovarian germ cell tumors. GynecolOncol. 2011;121:285-9.

Blom JW, Vanderschoot JPM, Oostindie MJ, Osanto S, van der Meer FJM, Rosendaal FR. Incidence of venous thrombosis in a large cohort of 66 329 cancer patients: results of a record linkage study. J Thromb Haemost. 2006;4:529-35.

Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111(10):4902-7.

Ay C, Vormittag R, Dunkler D. D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol. 2009;27(25):4124-9.